OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up

J. Sands, B.C. Cho, M.-J. Ahn, M. Reck, Jean G. Bustamante-Alvarez, H.-D. Hummel, Hiroko Akamatsu, M.L. Johnson, E. Felip, Sabin Handzhiev, I. Korantzis, H. Izumi, A.-M. Dingemans, F. Blackhall, T.K. Owonikoko, Jennifer Moriatis Wolf, Suresh S. Ramalingam, H. Borghaei, Shih-Cheng Huang, Tony Jiang, Erik S. Anderson, P. Martínez, Aziz Ahmad Hamidi, S. Mukherjee, L. Paz-Ares